miR-30b protects nigrostriatal dopaminergic neurons from MPP(+)-induced neurotoxicity via SNCA.

Brain and Behavior
Yu-Fei ShenYan-Ping Wang

Abstract

To explore the function of miR-30b in pathogenesis of Parkinson's disease (PD) and its underlying molecular mechanism. We used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPP(+)) as a tool for constructing the PD cell model, using miR-30b mimics or inhibitors to manipulate miR-30b level for an experimental model of acquisition. The cell viability of SH-SY5Y was detected by CCK, and luciferase was used to screen the binding of target genes. The protein levels of SNCA were measured by Western blot. Then, we investigate the changes in pro- and anti-apoptotic markers with or without miR-30b treatment. There was a significant low expression of MiR-30b in MPP(+)-induced cells. SH-SY5Y cell viability was rescued by MiR-30b overexpression. Luciferase experiments showed that MiR-30b may bind to the 3'-UTR side of SNCA and inhibited its expression. By Western blot, the SNCA level was markedly decreased by miR-30b. miR-30b attenuated the upregulation of Bax and the depletion of Bcl-2 induced by MPP(+).

References

Mar 1, 1990·Journal of Neurology, Neurosurgery, and Psychiatry·P B MatthewsN MacDermott
Aug 13, 1999·Genes & Development·A GrossS J Korsmeyer
Dec 25, 2002·Neurobiology of Aging·Heiko BraakEva Braak
Nov 1, 2003·Science·A B SingletonK Gwinn-Hardy
Feb 6, 2004·Journal of Neurochemistry·Tongguang WangJau-Shyong Hong
Sep 4, 2004·Genome Biology·Eric A MiskaH Robert Horvitz
Nov 23, 2006·Nature Reviews. Neuroscience·Kenneth S Kosik
Sep 1, 2007·Science·Jongpil KimAsa Abeliovich
Jan 22, 2008·Molecular Cell·Ligang Wu, Joel G Belasco
Apr 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·Sébastien S HébertBart De Strooper
Jan 2, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Amy N PackerBeverly L Davidson
Jun 3, 2011·European Journal of Epidemiology·Karin WirdefeldtJack Mandel
Sep 21, 2013·Neuron·Jacob T BendorRobert H Edwards
Nov 12, 2013·Progress in Neurobiology·Saeid GhavamiMarek J Łos
May 24, 2014·Pharmacology & Therapeutics·F I TaraziS A Mousa
Oct 30, 2016·International Journal of Molecular Sciences·Marcus O W GrimmTobias Hartmann
Mar 9, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Xian QinZhisu Liu
May 21, 2017·Experimental Brain Research·Abhishek Singh, Dwaipayan Sen
Aug 16, 2018·Saudi Journal of Biological Sciences·Daobao ZhangJianguo Xu
Oct 27, 2018·Movement Disorders Clinical Practice·Masoom M AbbasLouis C S Tan

❮ Previous
Next ❯

Citations

Sep 26, 2020·Journal of Cellular and Molecular Medicine·Xin WangTianyi Wang
Aug 6, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Han-A ParkKristi M Crowe-White
Jul 8, 2020·Antioxidants·Han-A Park, Amy C Ellis
May 18, 2021·Frontiers in Neuroscience·Yong Hui NiesSeong Lin Teoh
Sep 25, 2021·Molecular Medicine Reports·Yujing HuangLin Fan

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
PCR
Protein Assay

Software Mentioned

mirDIP
TargetScan
SPSS

Related Concepts

Related Feeds

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.